Abstract
The anti-angiogenic, carboxy terminal non-collagenous domain (NC1) derived from human Collagen type IV alpha 6 chain, [α6(IV)NC1] or hexastatin, was earlier obtained using different recombinant methods of expression in bacterial systems. However, the effect of L-arginine mediated renaturation in enhancing the relative yields of this protein from bacterial inclusion bodies has not been evaluated. In the present study, direct stirring and on-column renaturation methods using L-arginine and different size exclusion chromatography matrices were applied for enhancing the solubility in purifying the recombinant α6(IV)NC1 from bacterial inclusion bodies. This methodology enabled purification of higher quantities of soluble protein from inclusion bodies, which inhibited endothelial cell proliferation, migration and tube formation. Thus, the scope for L-arginine mediated renaturation in obtaining higher yields of soluble, biologically active NC1 domain from bacterial inclusion bodies was evaluated.
Keywords: Non-collagenous domain of α6 type IV collagen, L-arginine mediated renaturation, size exclusion chromatography, anti-angiogenic activity, human umbilical vein endothelial cells and vascular endothelial growth factor, inclusion bodies, blood capillaries
Protein & Peptide Letters
Title:L-arginine Mediated Renaturation Enhances Yield of Human, α6 Type IV Collagen Non-collagenous Domain from Bacterial Inclusion Bodies
Volume: 19 Issue: 10
Author(s): Venugopal Gunda, Chandra Shekhar Boosani, Raj Kumar Verma, Chittibabu Guda and Yakkanti Akul Sudhakar
Affiliation:
Keywords: Non-collagenous domain of α6 type IV collagen, L-arginine mediated renaturation, size exclusion chromatography, anti-angiogenic activity, human umbilical vein endothelial cells and vascular endothelial growth factor, inclusion bodies, blood capillaries
Abstract: The anti-angiogenic, carboxy terminal non-collagenous domain (NC1) derived from human Collagen type IV alpha 6 chain, [α6(IV)NC1] or hexastatin, was earlier obtained using different recombinant methods of expression in bacterial systems. However, the effect of L-arginine mediated renaturation in enhancing the relative yields of this protein from bacterial inclusion bodies has not been evaluated. In the present study, direct stirring and on-column renaturation methods using L-arginine and different size exclusion chromatography matrices were applied for enhancing the solubility in purifying the recombinant α6(IV)NC1 from bacterial inclusion bodies. This methodology enabled purification of higher quantities of soluble protein from inclusion bodies, which inhibited endothelial cell proliferation, migration and tube formation. Thus, the scope for L-arginine mediated renaturation in obtaining higher yields of soluble, biologically active NC1 domain from bacterial inclusion bodies was evaluated.
Export Options
About this article
Cite this article as:
Gunda Venugopal, Shekhar Boosani Chandra, Kumar Verma Raj, Guda Chittibabu and Akul Sudhakar Yakkanti, L-arginine Mediated Renaturation Enhances Yield of Human, α6 Type IV Collagen Non-collagenous Domain from Bacterial Inclusion Bodies, Protein & Peptide Letters 2012; 19 (10) . https://dx.doi.org/10.2174/092986612802762750
DOI https://dx.doi.org/10.2174/092986612802762750 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options
Current Cancer Drug Targets CYLD-Mediated Signaling and Diseases
Current Drug Targets Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews Epigenetic Modifications Due to Heavy Metals Exposure in Children Living in Polluted Areas
Current Genomics Intrinsic Properties of Mesemchymal Stem Cells from Human Bone Marrow, Umbilical Cord and Umbilical Cord Blood Comparing the Different Sources of MSC
Current Stem Cell Research & Therapy Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Epithelial-Mesenchymal Transition as a Therapeutic Target for Prevention of Ocular Tissue Fibrosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery Using Microgravity for Defining Novel Anti-Atherosclerotic Therapy
Current Genomics Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Metastasis-Associated Protein S100A4: Spotlight on its Role in Cell Migration
Current Cancer Drug Targets DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry A Review of Current Animal Models of Osteoarthritis Pain
Current Pharmaceutical Biotechnology Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis
Current Molecular Medicine